Fetal Fibronectin Testing

Pre-term birth is a significant health issue in Canada. In an effort to avoid unnecessary antepartum admissions or maternal transfers, many jurisdictions have adopted Fetal Fibronectin (ƒFN) testing for women with symptoms of pre-term labour. To assist health-care professionals and planners with the implementation and monitoring of a testing program, a Working Group with representatives from across Canada developed the following resources: a clinical guideline, a presentation, and a list of key indicators. These documents are provided as templates and can be adapted based on local circumstances.
RCP worked in collaboration with regional hospitals across Nova Scotia in 2006 to implement fetal fibronectin (fFN) testing to diagnose preterm labour. Dr. Heather Scott, Obstetrical Co-Director of RCP, Rebecca Attenborough, Coordinator RCP, and Mike Mahaffa, Adeza Biomedical Representative gave a presentation via telehealth on the implementation and use of fFN in Nova Scotia.